SureTrader SureTrader
Home > Boards > US Listed > Medical - Equipment >

Neovasc, Inc. (NVCN)

NVCN RSS Feed
Add NVCN Price Alert      Hide Sticky   Hide Intro
Moderator: CoinOp, saj, beambe, steez, l2 hunter, MANOLO1775
Search This Board:
Last Post: 12/9/2016 10:52:03 AM - Followers: 99 - Board type: Free - Posts Today: 17

{{{{{MAJOR UPDATE:ACQUISITION ALERT COLLABORATION WITH BOSTON SCIENTIFIC :Nasdaq"BSX" 

TAKING 15% OWNERSHIP STAKE IN: 
Nasdaq"NVCN" AND

US$75 MILLION AGREEMENT 12/02/16}}}}


                                                             
Neovasc and Boston Scientific Reach US$75 Million Agreement
12/2/2016 7:00:00 AM - PR Newswire

 
Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities
12/2/2016 7:00:00 AM - PR Newswire


MAJOR HOLDER OWNERSHIP ALSO RISES NOW TO 58 MILLION SHARES Direct Holders own 32mil ,Institutions 16mil,Mutual Funds 10mil , with new $BSX stake now added to Direct Holders

_________________________________________________________

Latest Analyst Ratings:

Leerink Reaffirms Neovasc (NVCN) at 'Outperform' Amid Boston Scientific Deal

December 2, 2016 11:57 AM 

Leerink affirms Neovasc Inc. (Nasdaq: NVCN) at Outperform with a price target of $10 following news of an asset sales agreement with Boston Scientific (NYSE: BSX)

http://www.streetinsider.com/dr/news.php?id=12306264


------------->>>VERY IN DEPTH DD HERE - ANOTHER MUST READ HERE 

Neovasc's Tiara and other TMVR devices

------------------------>>>>>>https://docs.google.com/document/d/1OvI4lcwVL_NbcH9SIveG-sWiSWfTfRUZxlxEcUV_5RA/edit
______________________________________________________________________________________________________________________
______________________________________________________________________________________________________________________
______________________________________________________________________________________________________________________



                                                                                                                                       
                                                                               
                       

                                                                                                       


                                                                                   Nasdaq: NVCN

                                                                                   
                                                                                      Contact Info
                                                                              
                                                                          
13562 Maycrest Way #5138, Richmond,

                                                                                  BC V6V 2j7 Canada
                                                                            Phone:1.604.270.4344
                                                                            Fax: 1.604.270.4384
                                                                            Email: info@neovasc.com
                                                                            Website: www.neovasc.com
                                                                 
          
                                                                                          


                                                                      About Neovasc                                                                        

                                                     Neovasc Inc. is a specialty medical device company that develops, manufactures,
                                                     and markets products for the rapidly growing cardiovascular marketplace.

                                                                        Our products include the Tiara™ technology in development for the transcatheter
                                                                        treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
                                                                        refractory angina.

                                                                         A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
                                                                         publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
                                                                         Exchange TSX: (NVC) 


 

Neovasc Tiara

Tiara is a novel transcatheter device designed to treat mitral regurgitation (MR), a condition that is often severe and can lead to heart failure and death.

Neovasc is developing the Tiara for the treatment of severe MR, a condition that affects approximately four million patients in the U.S. alone. Currently, conventional surgical treatments are only appropriate for about 20% of these patients, leaving the majority of patients untreated.

The Tiara device is delivered through the apex of the heart to replace the mitral valve while preserving the integrity of the surrounding structures of the heart.

Tiara has been designed specifically to address each of the challenges listed below and meet the need for transcatheter replacement of the mitral valve, rather than being adapted from an aortic valve. Tiara implantation is achieved through a transapical approach and does not require any hemodynamic support.
http://www.neovasc.com/products/neovasc-tiara/

                                                                                                                                                                                                
 

Neovasc Reducer

An effective percutaneous treatment for refractory angina, a severely debilitating condition that affects millions globally.

Resulting from inadequate blood flow to the heart muscle, refractory angina (RA) can often cause recurrent and severe heart pain that may be difficult to manage through conventional drug, catheter, or surgical therapy.  RA patients typically experience significant disability and impaired quality of life with few options for relief or improvement in their symptoms.

The Neovasc Reducer has been shown to be a safe and effective treatment for RA. Using a procedure similar to a coronary stent implantation, the Reducer procedure uses standard catheter-based techniques.

As with any medical procedure, there are risks associated with the use of the Neovasc Reducer™ System, including but not limited to myocardial infarction, continued angina, and implant migration/dislodgement requiring medical intervention. For a complete list of complications, see the Instructions for Use.
http://www.neovasc.com/products/neovasc-reducer/

                                                                                                             

__________________________________________________________________________________________________________________________________________________________                                                              

Opko Investee Neovasc $9B Massive and Virtually Unpenetrated Market Opportunity

                                   ****   Leerink Partners Starts Neovasc (NVCN) at Outperform, $15 PT ****


http://www.streetinsider.com/Analyst+Comments/Leerink+Partners+Starts+Neovasc+(NVCN)+at+Outperform,+$15+PT/10390409.html

https://opkodd.wordpress.com/2015/03/20/opko-investee-neovasc-9b-massive-and-virtually-unpenetrated-market-opportunity/
       
__________________________________________________________________________________________________________________________________________________________

                                          Successfully increasing financing year to year through Institutional Public Offerings
                              sets a tone to a growing Value in its Marketplace.


                                                               6-k dated May 2014 

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=10008601&RcvdDate=5/22/2014&CoName=NEOVASC%20INC&FormType=6-K&View=html 

"For the three months ended March 31, 2014, net cash provided by financing activities was $24,658,642 compared to $194,010 for the same period in 2013. On March 26, 2014, the Company closed a bought deal equity financing underwritten by Cormark Securities Inc., which placed 4,192,000 common shares of Neovasc at a price of $6.00 per common share, for gross cash proceeds to the Company of $25,152,000. The share issue cost was $506,651." 

                                                                6-k dated May 2015 

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=10691281&RcvdDate=5/12/2015&CoName=NEOVASC%20INC&FormType=6-K&View=html 


"For the three months ended March 31, 2015, net cash provided by financing activities was $88,143,429, compared to $24,658,642 for the same period in 2014. On February 3, 2015, the Company closed an underwritten public offering of 12,075,000 common shares of the Company (of which 10,415,000 common shares were issued from treasury and 1,660,000 common shares were sold by certain directors, officers and employees of the Company) at a price per share of US$7.19 for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the selling security holders. The share issue costs incurred by the Company were $6,236,783. "
_______________________________________________________________________________________________________________________________________________________________________________________________________________________


**NEWEST UPDATED INFO  6/15/16 - 6-K FILING SHOWS 81.28% Longs/Institutional Ownership from voting results**
 
NEOVASC INC.
(the “Company”)
 
Annual General Meeting of Shareholders
June 15, 2016
 
 
REPORT OF VOTING RESULTS
(Pursuant to Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations )
 
Common Shares represented at the Meeting:
 
54,540,817**
Total issued and outstanding Common Shares as at Record Date:
 
66,855,345
Percentage of issued and outstanding Common Shares represented:
 
81.58%
________________________________________________________________________________________________________________________________________________________

 http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11447721&RcvdDate=6/16/2016&CoName=NEOVASC%20INC&FormType=6-K&View=html
 

___________________________________________________________________________________________________________________________________________

 May 4 ,2016 6-k filing here has  #1 holder with 22.1% " Dr. Phillip Frost" of Frost Gamma Investments Trust  
 
Shareholder Name   Number of Shares Held     Percentage of Issued Shares  
             
Frost Gamma Investments Trust      14,786,219       22.1 %

  
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11400812&RcvdDate=5/20/2016&CoName=NEOVASC%20INC&FormType=6-K&View=html

_______________________________________________________________________________________________________________________________________________________________________________________________________________________

******Major Ownership Here: Funds & Institutions & Direct

Holders @Barrons has over

50+ Million Shares Owned !!! *****


****{ Major amount of this was purchased at the $6.00 & $7.19 level!! }



http://www.barrons.com/quote/stock/us/xnas/nvcn

_______________________________________________________________________________________________________________________________________________________________________________________________________________________
Latest Update here***********
As at November 14, 2016, the Company had 66,866,345 common voting shares issued and outstanding

Outstanding Share Data 
August 9, 2016, the Company had 66,866,345 common voting shares issued and outstanding
 
"Remaining Non Dilutive to Shareholders as Direct Funding has been their proven successful funding arena"


August 6, 2015, the Company had 66,551,447 common shares issued and outstanding
August 12, 2014, the Company had 53,756,932 common voting shares issued and outstanding

_______________________________________________________________________________________________________________________________________________________________________________________________________________________
 

Most recent broker ratings
 

05/20/2016 – Neovasc Inc. was downgraded to “neutral” by analysts at Ladenburg Thalmann.

03/30/2016 – Neovasc Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 9.5 price target on the stock.

10/07/2015 – JMP Securities began new coverage on Neovasc Inc. giving the company a “market outperform” rating. They now have a USD 10 price target on the stock.

09/23/2015 – Neovasc Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 20 price target on the stock.

03/31/2015 – Northland Securities began new coverage on Neovasc Inc. giving the company a “outperform” rating. They now have a USD 12 price target on the stock.

___________________________________________________________________________________________________________________________________________________________________________________________________________________

                                                    BUYOUT POTENTIAL                                        
              ------------------>>>>>>>>>>>>>Recent deals involving mitral valve companies<<<<<<<<<<<<<<--------------
"Great info and a MUST READ on the demand and for acquisitions for these type of companies here from last year this month now that remainder or any legal issues are getting ironed out through the final appeals days now , EVEN SHOWS THE $$ VALUES OF THE BOUGHT COMPANIES TOO:"
http://seekingalpha.com/article/3562756-boston-arrives-late-mitral-valve-party


""""UPDATE : NO INJUNCTION FOR TIARA DEVICE , CAN NOW MOVE FORWARD THUS MAKING IT MORE ATTRACTIVE FOR FUTURE BUYOUT"""""



                                                             





  Neovasc the small cap medical device company has a promising set of catalysts approaching for its core tissue division and for its two life saving vascular devices, The Reducer and The Tiara. The Reducer recently released extremely positive top line results of its sham-controlled COSIRA trial, and full results should be released by the end of the month. The device is already CE marked in Europe, and is the first minimally invasive treatment for Refractory Angina. Based off of comparable devices, the device can be worth anywhere from $5.00 to $14.00 per share.

The Tiara has received an extremely broad patent for treating Mitral Regurgitation, and is the frontrunner in bringing an effective product to the market for the first time ever. Neovasc tested the device in animals and recently published strong data supporting the safety and efficacy of the device. The first human implantation is scheduled for Q1 of 2014. If approved and brought to market, this would be a billion dollar device.

Neovasc's Peripatch tissue division continues to boast strong growth and profit numbers, as shown in its latest quarterly filing. This profitable division should see increased revenues as more of Neovasc's customers gain FDA approval for their vascular devices that utilize Neovasc's Peripatch tissue. The profit generated from the tissue division funds the development of The Reducer and The Tiara, which is unique for a small medical company, which would usually have to rely on secondary offerings (dilution) to generate the necessary development funds. The expanding growth of Neovasc and its tissue division will not end anytime soon as they finalize the divestment of its low margin patch division and benefit from the rapidly growing heart valve market.

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVCN
Current Price
Volume:
Bid Ask Day's Range
SureTrader
NVCN News: Report of Foreign Issuer (6-k) 12/06/2016 08:38:29 AM
NVCN News: Neovasc Provides Update on its Tiara™ Mitral Valve Clinical Program 12/06/2016 07:00:00 AM
NVCN News: Neovasc Provides Update on its Tiara™ Mitral Valve Clinical Program 12/06/2016 07:00:00 AM
NVCN News: Report of Foreign Issuer (6-k) 12/02/2016 07:51:06 AM
NVCN News: Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities 12/02/2016 07:00:00 AM
PostSubject
#2892  Sticky Note NVCN $10 TARGET AFTER MERGER NEWS >>> Leerink l2 hunter 12/05/16 08:35:45 AM
#1877  Sticky Note "Recent deals involving mitral valve companies" CoinOp 10/25/16 12:46:24 AM
#1857  Sticky Note NVCN $0.52 only 16m float / 66m O/S. l2 hunter 10/19/16 03:22:07 AM
#3658   Are we at 3 yet!! UP Trend 12/09/16 10:52:03 AM
#3657   Wow .. turning .. 100 m in cash Hana3 12/09/16 10:48:46 AM
#3656   See this is why listening to newbies will MANOLO1775 12/09/16 10:22:05 AM
#3654   $3 coming INFINITI 12/09/16 10:09:18 AM
#3653   good Volume beambe 12/09/16 09:57:18 AM
#3652   I believe so too. Gooo nvcn goo Phill-lecup 12/09/16 09:50:51 AM
#3651   Well back in @2.09 I believe in this Going2Pot 12/09/16 09:47:10 AM
#3650   $3 today maybe INFINITI 12/09/16 09:26:39 AM
#3649   Hope so , believe it is good Hana3 12/09/16 09:21:05 AM
#3648   $NVCN$ up premarket this ones a fast runner jboogie 12/09/16 09:05:47 AM
#3647   Going up today IMO INFINITI 12/09/16 08:25:35 AM
#3646   Why traders selling ? STOP NEXT 12/09/16 08:23:21 AM
#3645   LOL...nope. retireat40 12/09/16 08:11:40 AM
#3644   He hasn't posted here since Tuesday I believe. retireat40 12/09/16 08:04:55 AM
#3643   DID WE HIT 4-5? Peggy 12/09/16 05:23:08 AM
#3642   Tomorrow is the last day of the week. waterchaser 12/09/16 12:51:32 AM
#3641   Tomorrow's probably not gonna be a good day Short_moneyC3 12/08/16 09:24:51 PM
#3640   And red again, lol pberger 12/08/16 09:20:47 PM
#3639   Huh? Stocks aren't bonds lol. retireat40 12/08/16 08:05:13 PM
#3638   Careful you wont make money sitting on a INFINITI 12/08/16 06:35:07 PM
#3637   NVCN turning into long position, where it will Joecanada13 12/08/16 05:02:29 PM
#3636   * * $NVCN Video Chart 12-08-16 * * ClayTrader 12/08/16 04:24:38 PM
#3635   Actually it was a decent close thexsandos 12/08/16 04:01:12 PM
#3634   Terrible close. May end up LOD. retireat40 12/08/16 03:52:09 PM
#3633   That one had a nice pop but I retireat40 12/08/16 03:48:53 PM
#3632   $1.40 ish Gap will close.....unless great news hits NVCN stockdawg44 12/08/16 03:48:52 PM
#3631   10% of Tuesday's volume. Sub $2.00 again. Will retireat40 12/08/16 03:44:40 PM
#3629   http://seekingalpha.com/article/4029294-neovasc-soars-mitral-valves-head-europe Explorergypsy1 12/08/16 03:18:20 PM
#3628   ZZZZZZZZZZZZZZZZZzzzzzzzzzzzzzz looks like sideways trading for now. Needs retireat40 12/08/16 02:02:37 PM
#3627   Don't get caught with your pants down and greedkillsdeal$ 12/08/16 01:47:56 PM
#3626   Agree Dee, it time to see nice solid raggymoney 12/08/16 11:20:54 AM
#3625   2 share bid @ 2.10. Whos the guy The Deevs 12/08/16 11:14:29 AM
#3624   Here we go! Let's ride this tdot555 12/08/16 11:14:03 AM
#3623   Looks like it's getting ready to pop higher saj 12/08/16 11:06:26 AM
#3622   Nice solid buys coming in. The madness is The Deevs 12/08/16 11:06:05 AM
#3621   Nice INFINITI 12/08/16 11:02:37 AM
#3620   Still here brother. LOL The Deevs 12/08/16 11:01:07 AM
#3619   I only play my game. I appreciate the The Deevs 12/08/16 11:00:20 AM
#3618   Patience bud impatient looses money INFINITI 12/08/16 10:59:10 AM
#3617   How about now lol INFINITI 12/08/16 10:58:19 AM
#3616   Chart is setting up nicely. Alot of profit greedkillsdeal$ 12/08/16 10:56:28 AM
#3614   Question is will the bulls be ready force Mirk_Water 12/08/16 10:53:37 AM
#3613   Many who shorted have to cover today. $NVCN Mirk_Water 12/08/16 10:52:14 AM
#3612   Seems to be a little bit of covering DGilmour 12/08/16 10:48:02 AM
#3611   annnnnd look, we're Green ;-) time to Choo ChoO! DeadCellShadix 12/08/16 10:40:44 AM
#3610   Nice recovery. Push! greedkillsdeal$ 12/08/16 10:40:03 AM
#3609   Im not touching IMN# with a 10 foot The Deevs 12/08/16 10:37:50 AM
#3608   3.5 eod.. cashcow3 12/08/16 10:31:10 AM
#3607   Dee, what ever you do, do not, and raggymoney 12/08/16 10:30:59 AM
#3606   The relationship with BSX goes way back. Any JT230 12/08/16 10:19:12 AM
PostSubject